Sio Gene Therapies Equity 2024

Sio Gene Therapies Aktienanalyse

What does Sio Gene Therapies do?

Sio Gene Therapies Inc. is a biopharmaceutical company focused on developing gene therapies for rare genetic diseases. The company was founded in 2000 by a team of scientists specializing in the research of gene therapies for the treatment of rare diseases. Sio Gene Therapies' history began with the goal of providing an alternative treatment method for patients with rare diseases. The company focuses on the discovery and development of gene therapies based on the use of vectors to deliver genes into defective cells. The company has focused on diseases such as Huntington's chorea, Parkinson's disease, and rare hereditary diseases. Sio Gene Therapies' business model is designed to develop and market gene therapy as a novel therapy for rare diseases. The company pursues an innovative research program that aims to discover rare diseases and identify genetic mutations associated with these diseases. Sio Gene Therapies collaborates with leading scientists and research institutions to develop innovative approaches to the treatment of rare genetic diseases. Sio Gene Therapies has several divisions, including a research facility, a development department, and a sales department. Each of these departments plays a crucial role in the development of gene therapies for rare diseases. The research department identifies new target genes for the development of gene therapies, the development department develops and tests vectors for gene therapy, and the sales department works closely with physicians and health authorities to market and make gene therapy available. Sio Gene Therapies has developed a range of products based on gene therapy. This includes Axovant, a gene therapy for the treatment of Parkinson's disease that aims to deliver genes into defective cells. The drug is currently in the clinical testing stage. Peroxysome biogenesis disorder (PBD) is a rare hereditary disease caused by a dysfunction of peroxisomes. The company has already completed initial clinical studies with its product AXO-AAV-CLN6, a gene therapy approach for PBD. The results of these studies are promising, and the company is currently in Phase III of clinical studies. Sio Gene Therapies has achieved several milestones in recent years. In 2017, the company received approval from the U.S. Food and Drug Administration (FDA) for its first gene therapy for the treatment of rare degenerative retinal diseases. In August 2020, the company initiated a Phase III study for the treatment of PBD with AXO-AAV-CLN6. Overall, Sio Gene Therapies has established itself as a successful company in the gene therapy industry and has specialized in the development of gene therapies for rare genetic diseases. The company has made significant progress in the development of gene therapies in recent years and has also received important approvals from the FDA. Through ongoing research and development of new products, the company intends to contribute to the treatment and cure of rare genetic diseases in the future. Sio Gene Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Sio Gene Therapies's Equity

Sio Gene Therapies's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sio Gene Therapies's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sio Gene Therapies's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sio Gene Therapies's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sio Gene Therapies’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sio Gene Therapies stock

What is the equity of Sio Gene Therapies this year?

Sio Gene Therapies has equity of 60.3 M USD this year.

What was the equity of Sio Gene Therapies compared to the previous year?

The equity of Sio Gene Therapies has increased/decreased by -51.13% decreased compared to the previous year.

What impact does a high equity have on investors of Sio Gene Therapies?

A high equity is advantageous for investors of Sio Gene Therapies as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Sio Gene Therapies?

A low equity can be a risk for investors of Sio Gene Therapies, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Sio Gene Therapies affect the company?

An increase in equity of Sio Gene Therapies can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Sio Gene Therapies affect the company?

A reduction in equity of Sio Gene Therapies can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Sio Gene Therapies?

Some factors that can affect the equity of Sio Gene Therapies include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Sio Gene Therapies so important for investors?

The equity of Sio Gene Therapies is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Sio Gene Therapies take to change the equity?

To change equity, Sio Gene Therapies can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Sio Gene Therapies pay?

Over the past 12 months, Sio Gene Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sio Gene Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Sio Gene Therapies?

The current dividend yield of Sio Gene Therapies is .

When does Sio Gene Therapies pay dividends?

Sio Gene Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sio Gene Therapies?

Sio Gene Therapies paid dividends every year for the past 0 years.

What is the dividend of Sio Gene Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sio Gene Therapies located?

Sio Gene Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sio Gene Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sio Gene Therapies from 9/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Sio Gene Therapies pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Sio Gene Therapies in the year 2023?

In the year 2023, Sio Gene Therapies distributed 0 USD as dividends.

In which currency does Sio Gene Therapies pay out the dividend?

The dividends of Sio Gene Therapies are distributed in USD.